Engie Sa (EPA:ENGI) has been assigned a consensus recommendation of "Buy" from the nine brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The aver
Digital cues from online brokers or financial advisors have the potential to harm investors, by coaxing them to make decisions that end up costing them money.
That was a major takeaway from a Securities and Exchange Commission panel on Thursday meant to address the rise of new ways to buy stocks and options. The other major takeaway was that policing those digital cues is a complicated—if not impossible — task.
Members of the SEC Investor Advisory Committee met virtually to discuss the agency’s plans to address the “behavioral design of online platforms.” The SEC is....More>>>
Kin and Carta plc (LON:KCT)’s share price reached a new 52-week high on Wednesday . The company traded as high as GBX 315 ($4.12) and last traded at GBX 305 ($3.98), with a volume of 268643 shares traded. The stock had previously closed at GBX 308 ($4.02).
Separately, Numis Securities increased their price objective on Kin and Carta from GBX 240 ($3.14) to GBX 295 ($3.85) and gave the stock a “buy” rating in a research report on Tuesday, June 15th.
Get Kin and Carta alerts:
The firm has a market capitalization of £515.64 million and....More>>>
In the latest development pertaining to the takeover of the Kansas, MO-based railroad operator Kansas City Southern (KSU Quick QuoteKSU ) , Canadian Pacific Railway Limited’s (CP Quick QuoteCP ) $31-billion offer (inclusive of the $3.8-billion outstanding debt) is likely to be accepted by the former.
We remind investors that on Aug 31, the U.S. Surface Transportation Board (STB) rejected Canadian National’s proposal to set up a voting trust for the acquisition of Kansas City Southern. Following the STB decision, Canadian Pacific (its $31-billion bid was rejected earlier)....More>>>
I can see why contrarian investors may be interested in XPeng (NYSE:XPEV) stock. Shares in China-based electric vehicle (or EV) companies have fallen out of favor among investors, but the shift in sentiment has been the most dramatic among this particular name.
As a result of its extended price decline since June, Xpeng has become seemingly undervalued, if you compare its valuation (on a price/sales, or P/S, basis) to that of comparable names.
But while it’s true XPeng trades at a discount to its peers, that doesn’t make it a bargain. There’s a reason why XPEV....More>>>
The U.S. Food and Drug Administration (FDA) approved Comirnaty -- the COVID-19 vaccine co-developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) -- for use in people aged 16 and older on Monday. The news drove shares of Pfizer and BioNTech up 2.5% and 9.6%, respectively. Fell